Home > Back to Publisher > Report Information

Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders

CHI Insight Pharma Reports
December 1, 2008
148 Pages - SKU: CHI2065276

Abstract Table of Contents Related Reports

Neurodegenerative diseases are drawing immense interest from the pharmaceutical industry and have inspired heavy competition in the race to introduce the next generation of improved drugs. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis are analyzed in this report, which:

Reviews their symptoms and pathology, presumed causes, methods of diagnosis, epidemiology
Examines existing drug therapies for each disorder
Surveys the R&D picture for each disease
Tabulates the approximately 150 compounds in clinical development
Discusses particularly noteworthy drug candidates.

Neurodegenerative diseases are caused by the loss or dysfunction of neurons in the brain or spinal cord. These diseases are especially devastating because the affected cells typically cannot regenerate following damage or death. Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders deals with chronic neurodegenerative diseases by focusing on four of the most comprehensively studied such conditions: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS).

Chapter 1
INTRODUCTION AND REVIEW OF THE NEURODEGENERATIVE DISEASES: PATHOLOGY, CAUSES, DIAGNOSIS, AND EPIDEMIOLOGY: 1.1. Report Focus: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Amyotrophic Lateral Sclerosis; 1.2. Report Organization; 1.3. Alzheimer’s Disease; 1.4. Parkinson’s Disease; 1.5. Huntington’s Disease; 1.6. Amyotrophic Lateral Sclerosis
Chapter 2
CURRENT PHARMACOLOGIC TREATMENT OPTIONS: 2.1. Alzheimer’s Disease; 2.2. Parkinson’s Disease; 2.3. Huntington’s Disease; 2.4. Amyotrophic Lateral Sclerosis
Chapter 3
COMPOUNDS IN DEVELOPMENT: THE NEXT GENERATION OF DRUGS FOR NEURODEGENERATIVE DISEASES: 3.1. Alzheimer’s Disease; TorreyPines Therapeutics; Merck & Co.; ANAVEX Life Sciences; Medivation/Pfizer; Lexicon Pharmaceuticals; Addex Pharmaceuticals; EPIX Pharmaceuticals/GlaxoSmithKline; Suven Life Sciences; Memory Pharmaceuticals; Eli Lilly; Humanetics/Mount Sinai School of Medicine; ExonHit Therapeutics; Eisai; CoMentis/Astellas Pharma; Noscira; JADO Technologies; RemeGenix; Medisyn Technologies; Neurobiological Technologies; Galapagos; Others; Elan/Wyeth; Eli Lilly; Novartis Pharma/Cytos Biotechnology; Merck & Co./Acumen Pharmaceuticals; Intellect Neurosciences; Others; Pfizer/TransTech Pharma; BELLUS Health; Prana Biotechnology; 3.2. Parkinson’s Disease; Intra-Cellular Therapies; Adenosine A2A Receptor Modulation; Biogen Idec/Vernalis; Schering-Plough; Synosia Therapeutics; Others; Faust Pharmaceuticals; Addex Pharmaceuticals/Merck & Co.; Neurim Pharmaceuticals; VistaGen Therapeutics; Santhera Pharmaceuticals/Juvantia Pharma; TauRx Pharmaceuticals; FoldRx Pharmaceuticals; ProteoTech; BioArctic Neuroscience; Rentschler Biotechnologie; Prana Biotechnology; Panacea Pharmaceuticals; Alnylam Pharmaceuticals; Aeolus Pharmaceuticals; Vasogen; Trophos; Zenobia Therapeutics; Neurologix; Ceregene/Genzyme; Oxford BioMedica; Amsterdam Molecular Therapeutics; NeuroNova; NsGene; ArmaGen Technologies; Sangamo BioSciences; 3.3. Huntington’s Disease; NeuroSearch; Cortex Pharmaceuticals; VistaGen; Isis Pharmaceuticals; Targeted Genetics; Alnylam Pharmaceuticals/Medtronic; Raptor Pharmaceuticals; Repligen; Prana Biotechnology; Adeona Pharmaceuticals; Vertex Pharmaceuticals; Amarin; Intellect Neurosciences; Trophos; Neurologix; KeyNeurotek Pharmaceuticals; Ceregene; ENKAM Pharmaceuticals; Neurobiological Technologies; 3.4. Amyotrophic Lateral Sclerosis; Teva Pharmaceutical Industries; Faust Pharmaceuticals; CytRx; Isis Pharmaceuticals; Neuroprotection; Trophic Factors; Insmed; Microtubule Stabilization; KineMed
Chapter 4
CONCLUSIONS AND OUTLOOK
Tables and Figures: Figure 1.1. Amyloid Cascade Mechanism; Figure 2.1. Treatment Algorithm for Mild-to-Moderate Alzheimer’s Disease; Figure 2.2. Treatment Algorithm for Moderate-to-Severe Alzheimer’s Disease; Figure 2.3. Treatment Algorithm for Severe Alzheimer’s Disease; Figure 2.4. Treatment Algorithm for Parkinson’s Disease; Table 1.1. NINDS Diagnostic Criteria for Parkinson’s Disease; Table 1.2. Revised El Escorial World Federation of Neurology Criteria for ALS; Table 3.1. Drugs in Clinical Trials for Alzheimer’s Disease; Table 3.2. Drugs in Clinical Trials for Parkinson’s Disease; Table 3.3. Drugs in Clinical Trials for Huntington’s Disease; Table 3.4. Drugs in Clinical Trials for Amyotrophic Lateral Sclerosis

Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service